Most Recent
A judge has taken a hatchet to Quinn Emanuel's fees and the funder's cut in a $12 million settlement of a class action against Bank of Queensland, a settlement which he previously described as one of the "worst" he'd ever seen.
The Australian Securities and Investments Commission claims Rio Tinto's former CFO was referring to the write down for the reserves for two coal assets that were part of a $4 billion acquisition of Rio Tinto Coal Mozambique when he sent an email to the company CEO in January 2012 that contained the phrase "worse by far than expected".
Bank of Queensland has lost a dispute with two insurers over coverage for a $6 million settlement of a class action brought by investors in a Ponzi scheme by jailed scammer Bradley Sherwin, with a judge shooting down the bank's argument that the class action should only be considered one claim under the policy.
Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.
Generic drug maker Alphapharm has lost another bid for documents from Sanofi-Aventis in advance of a hearing on Sanofi's interlocutory application seeking to block the generic drug maker from listing its injector pen on the Pharmaceutical Benefits Scheme.
A South Korean biotech company has filed an appeal with the Federal Court after an Ashurst partner succeeded in opposing the company's proposed patent for a genome editing technology.
Crown Resorts has accused the NSW government of breaching its contractual obligations by "spruiking" to construction firms for development at central Barangaroo that would obstruct its views of the Sydney Harbour Bridge and the Opera House.
A patent for genome editing technology by a South Korean biotechnology company has been rejected for a lack of clarity, novelty, and inventiveness, but the Australian Patent Office has given the company two months to try again.
Generic drug company Alphapharm has lost a bid for documents it claimed would show Sanofi-Aventis suspected as early as 2015 that patents for one of its injector pens may be invalid.
Generic drug maker Alphapharm is fighting a bid by global pharmaceutical giant Sanofi-Aventis to block the listing of one of its injector pens, saying the proposed injunction should be denied because Sanofi is seeking to amend the patent at issue.